Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars
Executive Summary
Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.
You may also be interested in...
Lupin Awaits 'Clarity' On Albuterol Filing
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
Lupin US Launches On Track But Albuterol 'Clarity' Awaited
After lower growth in India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes
Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.